PSL-BIC : Dani Gibson

Détails de l'événement

Multi-Action Platinum Anticancer Agents

To overcome the drawbacks of the clinically used Pt(II) drugs, we designed muti-action Pt(IV) prodrugs that can release inside the cancer cells two, three or four bioactive moieties that have different cellular targets. This approach enhances the chances of killing the cancer cells. These compounds are very potent cytotoxic agents that were particularly effective against KRAS mutated cancers such as colon and pancréas.